Induced pluripotent stem cell therapeutic - Myogenica
Alternative Names: MyoPAXonLatest Information Update: 25 Nov 2024
Price :
$50 *
At a glance
- Originator Myogenica
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 18 Nov 2024 Myogenica plans a phase I trial for Duchenne muscular dystrophy in December 2024 (IM) (NCT06692426)
- 17 Jul 2024 Preclinical trials in Duchenne muscular dystrophy in USA (Parenteral), prior to July 2024
- 17 Jul 2024 US FDA approves IND application for Induced pluripotent stem cell therapeutic in Duchenne muscular dystrophy